BioCryst Pharmaceuticals’ (BCRX) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report published on Thursday,Benzinga reports. The firm currently has a $15.00 target price on the biotechnology company’s stock.

A number of other equities analysts have also commented on the stock. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Wedbush began coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and set a $11.00 price objective (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Finally, Evercore ISI increased their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Stock Performance

BCRX stock opened at $6.82 on Thursday. The firm has a market cap of $1.43 billion, a P/E ratio of -11.18 and a beta of 1.75. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $9.50. The stock has a 50-day simple moving average of $7.96 and a 200-day simple moving average of $7.74.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same period last year, the business earned $0.28 earnings per share. The firm’s quarterly revenue was up 40.8% compared to the same quarter last year. On average, equities research analysts predict that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock valued at $164,616,000 after acquiring an additional 1,583,826 shares in the last quarter. Principal Financial Group Inc. increased its stake in BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after purchasing an additional 375,890 shares during the last quarter. Teacher Retirement System of Texas raised its holdings in shares of BioCryst Pharmaceuticals by 25.1% during the fourth quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company’s stock worth $438,000 after purchasing an additional 11,711 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of BioCryst Pharmaceuticals by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock worth $14,890,000 after buying an additional 91,998 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after buying an additional 127,708 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.